Biogen Inc (BIIB) : Terril Brothers added new position in Biogen Inc during the most recent quarter end. The investment management firm now holds 65,573 shares of Biogen Inc which is valued at $20,585,988 , the company said in a statement filed on Aug 10, 2016 with the SEC.Biogen Inc makes up approximately 8.63% of Terril Brothers’s portfolio.
Other Hedge Funds, Including , Pinebridge Investments reduced its stake in BIIB by selling 265 shares or 15.34% in the most recent quarter. The Hedge Fund company now holds 1,463 shares of BIIB which is valued at $459,294. Biogen Inc makes up approx 0.02% of Pinebridge Investments’s portfolio.Commerce Bank reduced its stake in BIIB by selling 37 shares or 0.13% in the most recent quarter. The Hedge Fund company now holds 27,675 shares of BIIB which is valued at $8,703,511. Biogen Inc makes up approx 0.13% of Commerce Bank’s portfolio.Robshaw Julian Associates Inc reduced its stake in BIIB by selling 345 shares or 5.78% in the most recent quarter. The Hedge Fund company now holds 5,620 shares of BIIB which is valued at $1,775,695. Biogen Inc makes up approx 1.29% of Robshaw Julian Associates Inc’s portfolio.Buckingham Asset Management boosted its stake in BIIB in the latest quarter, The investment management firm added 15 additional shares and now holds a total of 865 shares of Biogen Inc which is valued at $277,959. Biogen Inc makes up approx 0.09% of Buckingham Asset Management’s portfolio.Duff Phelps Investment Management Co reduced its stake in BIIB by selling 170 shares or 5.52% in the most recent quarter. The Hedge Fund company now holds 2,910 shares of BIIB which is valued at $843,696. Biogen Inc makes up approx 0.01% of Duff Phelps Investment Management Co’s portfolio.
Biogen Inc opened for trading at $313.69 and hit $319.89 on the upside on Friday, eventually ending the session at $316.81, with a gain of 1.09% or 3.43 points. The heightened volatility saw the trading volume jump to 13,93,517 shares. Company has a market cap of $69,420 M.
On the company’s financial health, Biogen Inc reported $5.21 EPS for the quarter, beating the analyst consensus estimate by $ 0.52 according to the earnings call on Jul 21, 2016. Analyst had a consensus of $4.69. The company had revenue of $2894.00 million for the quarter, compared to analysts expectations of $2790.65 million. The company’s revenue was up 11.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted $4.22 EPS.
Many Wall Street Analysts have commented on Biogen Inc. Biogen Inc was Initiated by Bernstein to “Outperform” on Jun 29, 2016. Biogen Inc was Downgraded by Citigroup to ” Neutral” on Jun 7, 2016.
Biogen Inc. formerly Biogen Idec Inc. is a global biopharmaceutical company. The Company is focused on discovering developing manufacturing and delivering therapies for neurological autoimmune and hematologic disorders. The Company develops manufactures and markets products designed for the treatment of multiple sclerosis (MS) and hemophilia A and B. The Company’s marketed products include AVONEX PLEGRIDY TECFIDERA TYSABRI FAMPYRA for multiple sclerosis (MS) ALPROLIX for hemophilia B and ELOCTATE for hemophilia A among others. It also collaborates on the development and commercialization of RITUXAN (rituximab) which is a monoclonal antibody for the treatment of non-Hodgkin’s lymphoma chronic lymphocytic leukemia and other conditions and share profits and losses for GAZYVA which is for the treatment of chronic lymphocytic leukemia.